Expanding Access to Diabetes Self-Management Training Act of 2025

The 'Expanding Access to Diabetes Self-Management Training Act of 2025' (HR3826) was introduced in the House on June 6, 2025, and subsequently referred to the Committees on Energy and Commerce and Ways and Means. This bill seeks to amend the Social Security Act to improve access to diabetes outpatient self-management training services under Medicare. Specifically, it expands who can provide these services beyond physicians to include other healthcare practitioners, increases the covered training hours to an initial 10 hours and an additional 2 hours annually, and prohibits the Centers for Medicare & Medicaid Services from limiting medically necessary training. The bill also requires the Center for Medicare and Medicaid Innovation to test a model for virtual diabetes outpatient self-management training services. This bill does not explicitly authorize or appropriate a specific dollar amount. Instead, it modifies Medicare coverage rules, which would lead to increased reimbursement for diabetes self-management training services and associated technologies. The funding mechanism would be through the existing Medicare system, with an expansion of covered services. This means that while no new direct appropriation is made, the total spending within Medicare for these services would likely increase if the bill becomes law, benefiting providers and manufacturers whose products and services fall under the expanded coverage. Structural winners from this legislation, if enacted, would be companies involved in diabetes care technology, diagnostic services, and healthcare providers offering diabetes self-management training. Companies like DexCom ($DXCM) and Abbott Laboratories ($ABT), which produce continuous glucose monitoring (CGM) devices, and Medtronic plc ($MDT), which offers various diabetes management solutions, could see increased demand as more patients access training and potentially adopt these technologies. Diagnostic companies such as Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) could also benefit from increased diagnostic testing associated with expanded diabetes management. The bill's focus on virtual training also presents an opportunity for companies developing telehealth and remote patient monitoring solutions. As of today, 2026-04-07, the bill is in an early stage of the legislative process, having been referred to committees. There is a companion bill, S1925, in the Senate, which indicates bipartisan and bicameral interest, potentially increasing its chances of eventual passage. However, significant legislative steps, including committee review, potential amendments, and votes in both chambers, remain. The current market data shows mixed performance for the identified companies. Over the last 30 days, $DXCM is down 7.67%, $ABT is down 6.57%, and $MDT is down 5.07%. In contrast, $LH is up 1.47% and $DGX is up 0.58% over the same period. These movements reflect broader market dynamics and company-specific news, as the bill's early stage means its potential impact is not yet priced into current valuations. The next steps for HR3826 involve committee hearings and markups in the House Energy and Commerce and Ways and Means Committees. If it passes out of committee, it would then be eligible for a vote by the full House. A similar process would occur in the Senate for S1925. The presence of a companion bill suggests a coordinated effort to advance this policy.